Today: 21 May 2026
Boeing stock jumps as deliveries hit 7-year high and orders beat Airbus
13 January 2026
2 mins read

Boeing stock jumps as deliveries hit 7-year high and orders beat Airbus

NEW YORK, Jan 13, 2026, 14:39 EST

  • Boeing shares gained roughly 2.6% after the company announced it delivered 600 jets in 2025
  • Net orders after cancellations hit 1,075, surpassing Airbus’ 889
  • Delta placed an order for 30 787-10s, with options to buy 30 additional aircraft; lessor ACG secured an order for 50 737 MAX jets

Boeing (BA.N) shares jumped 2.6% to $246.04 in Tuesday afternoon trading following the announcement of its highest annual jet deliveries since 2018. The planemaker reported 600 aircraft delivered in 2025, a 72% increase, and net orders—bookings after cancellations—hit 1,075, surpassing Airbus’ 889. Airbus, however, still led in deliveries with 793 jets. Boeing’s finance chief said the company expects to generate positive cash flow in 2026, supported by increased commercial deliveries.

Boeing’s cash flow hinges largely on jet deliveries, making the delivery count crucial. The company handed over 600 aircraft in 2025, a sharp rise from 348 the previous year, according to FlightGlobal. By year-end, Boeing’s backlog—the pool of unfulfilled orders—stood at 6,130 jets. FlightGlobal also reported that customers placed orders for 381 787 Dreamliners and 601 737s during the year.

Boeing reported delivering 160 commercial planes in Q4, with 117 of those being 737s and 27 787s. The 737 remains the company’s main single-aisle model, while the 787 serves longer-haul routes as a twin-aisle jet. For the full year, Boeing handed over 447 737s and 88 787s, along with smaller shipments of 767s and 777s.

Orders continue to roll in as 2026 begins. Delta Air Lines placed its first direct order with Boeing for 30 787-10s, along with options on 30 more, aiming to modernize its long-haul fleet. “Delta is building the fleet for the future,” said CEO Ed Bastian. Stephanie Pope, head of Boeing Commercial Airplanes, called the move “a perfect fit” for the airline’s international expansion. MediaRoom

Delta plans to start receiving its 787-10s in 2031, according to Reuters. The airline described the move as a way to reduce dependence on a single supplier, after years of focusing on Airbus for its widebody fleet expansion. “It’s pretty tough to operate… being reliant on only a single-source provider,” CEO Bastian said. Shares of Delta dropped about 3% Tuesday following a profit forecast that missed expectations. Reuters

Boeing unveiled a fresh 737 MAX deal with aircraft lessor Aviation Capital Group (ACG), involving 50 jets split evenly between 25 737-8s and 25 of the bigger 737-10s. “This order… supports a key pillar of our growth strategy,” said ACG CEO Thomas Baker, noting the delivery slots run from 2026 through 2033. Boeing sales chief Brad McMullen described the larger 737-10 order as a sign of “strong confidence” in the aircraft. MediaRoom

The rebound remains fragile. A drop in manufacturing quality, hold-ups in regulatory approval for new models, or supplier bottlenecks could stall deliveries and tighten cash flow once more.

Boeing plans to release its fourth-quarter results on Jan. 27. CEO Kelly Ortberg and CFO Jay Malave will outline the outlook during a conference call. Investors are focused on production rates and whether deliveries are boosting cash flow.

Airbus still leads in production volume, but both manufacturers are scrambling over limited delivery slots while airlines push for more capacity. Boeing’s recent figures show it’s shipping more planes and scoring bigger deals, yet the market keeps a close eye on factory output just as much as on orders.

Stock Market Today

  • CyberTech Systems Earnings Raise Cash Flow Concerns Amid Market Stability
    May 20, 2026, 8:56 PM EDT. CyberTech Systems and Software Limited (NSE:CYBERTECH) posted earnings that met market expectations but revealed an accrual ratio of 0.53, indicating weaker free cash flow relative to profit. This financial metric, which measures non-cash earnings, signals potential challenges for upcoming profits as free cash flow of ₹76 million lagged behind reported profit of ₹304.3 million for the year ending March 2026. Despite a 28% annual growth in earnings per share (EPS) over three years, the decline in cash conversion may raise investor caution. The company's accrual ratio improved last year, suggesting the current shortfall could be temporary, but shareholders are advised to monitor cash flow trends closely against profitability for a clearer outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Fabrinet (FN) stock jumps 8% after CPI report as traders eye next earnings test
Previous Story

Fabrinet (FN) stock jumps 8% after CPI report as traders eye next earnings test

iRhythm (IRTC) stock slides as 2026 outlook and holding-company switch land
Next Story

iRhythm (IRTC) stock slides as 2026 outlook and holding-company switch land

Go toTop